




FIG. 1A





FIG. 1B






FIG. 3A




FIG. 3B




FIG. 3C




FIG. 4A




FIG. 4B




FIG. 5




FIG. 6




FIG. 7B







FIG. 7A








FIG. 9B




FIG. 9A




FIG. 9D




FIG. 9C






FIG. 10A







FIG. 10D



FIGS. 11A-D




FIG. 12B







FIG. 12A





Data are shown as individual data points (n=2-3) and means and SEM are also shown. # denotes scores combined to determine the NAF LD activity score (NAS). There is insufficient power to achieve statistical significance.

FIGS 14A-E



Data are shown as individual data points (n=4) and means and SEM are also shown. # denotes scores combined to determine the NAFLD activity score (NAS). Comparisons to the placebo group and to the Diazoxide group are denoted by *p<0.05.

FIGS. 15A-E




FIG. 16B

FIG. 16A




FIG. 17B




FIG. 17A

SURx/Kirx Channel Activator I and MC4R Agonist I
Concentrations in Liver, CSF, and Plasma

Test articles	CSF ng/mL	Liver ng/mL	Plasma ng/mL	Liver/ Plasma*	CSF/ Plasma*
(100mg/kg/d)	535 ± 69.4	25,133 ± 3063.9	27,660 ± 1861.9	0.91	0.62
Combo arm SURx/Kirx Channel Activator I (100 mg/kg/d) + MC4R Agonist I (5 mg/kg)	429 ± 83.9	23,714 ± 2975.1	31,371 ± 2377.1	0.76	0.614
	0.59 ± 0.091	12.7 ± 1.23	27.6 ± 2.8	0.46	0.62

FIG. 18




FIG. 19A




FIG. 19B




FIG. 19C




FIG. 19D